Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 3/20 | 0.52 |
| ▸ | CTSK | P43235 | 3/20 | 0.52 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.46 |
| ▸ | SCN9A | Q15858 | 12/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | JAK3 | P52333 | 1/20 | 0.41 |
| ▸ | BTK | Q06187 | 1/20 | 0.41 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.38 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.37 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8272558 | 1.00 | CTSS (0.52) | CTSSCTSKPTPN1SCN9AATM | |
| SCHEMBL5561946 | 0.87 | CTSS (0.52) | CTSSCTSKPTPN1SCN9AATM | |
| SCHEMBL5561944 | 0.87 | CTSS (0.52) | CTSSCTSKPTPN1SCN9AATM | |
| SCHEMBL3997764 | 0.84 | CTSS (0.60) | CTSSCTSKPTPN1SCN9AATM | |
| SCHEMBL4896150 | 0.84 | CTSS (0.60) | CTSSCTSKPTPN1SCN9AATM | |
| SCHEMBL4663069 | 0.84 | CTSS (0.57) | CTSSCTSKPTPN1SCN9AATM | |
| SCHEMBL17015 | 0.84 | CTSS (0.60) | CTSSCTSKPTPN1SCN9AATM | |
| SCHEMBL30753714 | 0.84 | CTSS (0.60) | CTSSCTSKPTPN1SCN9AATM | |
| SCHEMBL5565378 | 0.83 | CTSS (0.48) | CTSSCTSKPTPN1SCN9AATM | |
| SCHEMBL8279767 | 0.83 | CTSS (0.48) | CTSSCTSKPTPN1SCN9AATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080176838-A1 | Dpp-IV Inhibitors | SANTHERA PHARMACEUTICALS (DEUTSCHLAND) AG (DE) | 2008-07-24 | — | — | US | disclosed |
| EP-1604662-A1 | 1-[(3R)-Amino-4-(2-fluoro-phenyl)-butyl]-pyrrolidine-(2R)-carboxylic acid benzyl amine derivatives and related compounds as dipeptidyl peptidase IV (DPP-IV) inhibitors for the treatment of type 2 diabetes mellitus | Santhera Pharmaceuticals (Deutschland) Aktiengesellschaft (DE) | 2005-12-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176838-A1 | Dpp-IV Inhibitors | DPP4, DPP9, DPP7 | CTSS 1262/4885CTSK 786/4885PTPN1 228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.